Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study ONCOLOGIST Roncolato, F. T., Joly, F., O'Connell, R., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, J. S., Heitz, F., Feeney, A., Berton-Rigaud, D., Stockler, M. R., King, M., Friedlander, M., GCIG Symptom Benefit Grp 2017; 22 (9): 1117–24

Abstract

Clinicians and patients often overestimate the benefits of chemotherapy, and overall survival (OS), in platinum resistant/refractory ovarian cancer (PRROC). This study sought to determine aspects of health-related quality of life and clinicopathological characteristics before starting chemotherapy that were associated with stopping chemotherapy early, shortened survival, and death within 30 days of chemotherapy.This study enrolled women with PRROC before starting palliative chemotherapy. Health-related quality of life was measured with EORTC QLQ-C30/QLQ-OV28. Chemotherapy stopped within 8 weeks of starting was defined as stopping early. Logistic regression was used to assess univariable and multivariable associations with stopping chemotherapy early and death within 30 days of chemotherapy; Cox proportional hazards regression was used to assess associations with progression-free and OS.Low baseline global health status (GHS), role function (RF), physical function (PF), and high abdominal/gastrointestinal symptom (AGIS) were associated with stopping chemotherapy early (all p?

View details for DOI 10.1634/theoncologist.2017-0047

View details for Web of Science ID 000410656500017

View details for PubMedID 28596446

View details for PubMedCentralID PMC5599194